StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) shareholders

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.24−0.08 (-1.09%)

Close on Nov 17, 2026Market cap $477.94MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
64.2%
42M of 66M shares
Institutional holders
165
25 new, 35 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
2 buys · 5 sales
Net bought $9.57K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Redmile Group, LLC
Joint filing with Jeremy C. Green (9.90%), Redmile Biopharma Investments III, L.P. (7.40%)
5,062,4779.90%13G (passive) amendmentJun 30, 2025
BlackRock, Inc.3,678,7387.30%13G (passive) amendmentMar 31, 2025
JPMorgan Chase & Co.3,560,9155.30%13G (passive)Sep 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of RGNXValueChange% of portfolio
BlackRock, Inc.6,397,4409.69%$76.64M+614,6320.00%
Redmile Group, LLC4,368,8046.62%$52.34M–3.51%
State Street Corp2,971,1734.50%$35.59M+239,6880.00%
JPMorgan Chase & Co2,214,1693.35%$26.19M−1,269,6310.00%
Vanguard Capital Management LLC2,107,5573.19%$25.25M+100,4110.00%
Morgan Stanley1,953,2372.96%$23.40M−112,9200.00%
Goldman Sachs Group Inc1,421,4532.15%$17.03M−418,0100.00%
Aqr Capital Management LLC1,378,3582.09%$16.51M+326,6460.01%
Vanguard Portfolio Management LLC1,355,5542.05%$16.24M+336,6530.00%
Marshall Wace, Llp1,284,9501.95%$15.39MNew0.01%
Geode Capital Management, LLC1,241,2961.88%$14.87M+103,7980.00%
Integral Health Asset Management, LLC800,0001.21%$9.58M−700,0000.38%
Nuveen, LLC740,0261.12%$8.87M+158,0100.00%
Dimensional Fund Advisors LP731,5861.11%$8.76M−278,7950.00%
D. E. Shaw & Co., Inc.712,8141.08%$8.54M+426,8130.00%
Two Sigma Investments, LP669,8081.01%$8.02M+114,9160.01%
Citadel Advisors LLC669,0231.01%$8.01MNew0.00%
Stifel Financial Corp560,7270.85%$6.72M+167,9580.01%
Bank Of America Corp /De/518,5450.79%$6.21M+193,6850.00%
22NW, LP492,7590.75%$5.90M–5.64%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202616542M64.2%25 / 6252 / 357M8M
Q1 202617843M64.6%33 / 6059 / 268M3M
Q4 202517441M62.4%24 / 6360 / 144M8M
Q3 202516645M68.8%23 / 6452 / 158M5M
Q2 202515942M63.7%25 / 6051 / 287M6M
Q1 202516442M63.1%34 / 5153 / 446M6M
Q4 202417742M63.8%39 / 5751 / 447M11M
Q3 202418646M69.9%31 / 6550 / 2513M5M
Q2 202418147M70.8%25 / 7448 / 305M7M
Q1 202418849M74.2%40 / 6152 / 238M3M
Q4 202317144M66.5%32 / 4761 / 2011M4M
Q3 202315937M56.3%17 / 6252 / 252M2M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

174 funds held RGNX in Q2 2026, 56% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of RGNXValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF1,958,9762.97%$23.47M0.22%Jun 30, 2026
Vanguard Total Stock Market Index Fund1,496,1392.27%$17.92M0.00%Jun 30, 2026
iShares Russell 2000 ETF1,270,4551.92%$15.22M0.02%Jun 30, 2026
Nuveen Quant Small Cap Equity Fund855,1701.30%$8.29M0.20%Jul 31, 2026
JPMorgan Small Cap Growth Fund629,8430.95%$7.55M0.29%Jun 30, 2026
Vanguard Extended Market Index Fund564,4760.86%$6.76M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund527,9350.80%$5.12M0.02%Jul 31, 2026
Vanguard Strategic Small-Cap Equity Fund467,2480.71%$5.60M0.18%Jun 30, 2026
iShares Russell 2000 Growth ETF378,1180.57%$4.53M0.03%Jun 30, 2026
BlackRock Advantage Small Cap Core Fund339,9570.51%$2.38M0.05%May 29, 2026
iShares Biotechnology ETF336,1790.51%$4.03M0.04%Jun 30, 2026
Fidelity Enhanced Small Cap Core ETF322,7700.49%$3.87M0.07%Jun 30, 2026
Vanguard Market Neutral Fund281,9850.43%$3.38M0.57%Jun 30, 2026
Fidelity Extended Market Index Fund246,9360.37%$1.73M0.00%May 31, 2026
Vanguard Russell 2000 Index Fund242,4680.37%$1.70M0.01%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Curran SimpsonChief Executive Officer, Director338,0530.51%Jul 6, 2026
Craig MalzahnChief Technology Officer109,7370.17%Nov 3, 2026
Mitchell ChanChief Financial Officer147,1200.22%Nov 3, 2026
Patrick J. ChristmasChief Strategy & Legal Officer240,6900.36%Nov 3, 2026
Steve PakolaChief Medical Officer240,2630.36%Nov 3, 2026
Olivier DanosChief Scientific Officer226,3480.34%Apr 4, 2025
Gregory Austin CiongoliDirector118,0350.18%Aug 27, 2026
Daniel TasseDirector28,8610.04%Jun 2, 2026
George V. MigauskyDirector28,8610.04%Jun 2, 2026
Jean BennettDirector28,8610.04%Jun 2, 2026
Jennifer ZacharyDirector31,8710.05%Jun 2, 2026
Argeris N. KarabelasDirector28,8610.04%Jun 2, 2026
David C. StumpDirector28,8610.04%Jun 2, 2026
Kenneth T. MillsDirector495,9250.75%Jun 2, 2026
Allan M. FoxDirector2,911,3274.41%Jun 2, 2026
Alexandra GlucksmannDirector28,8610.04%Jun 2, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Craig Malzahn
Chief Technology Officer
Nov 1, 2026Award+27,777––109,737
Mitchell Chan
Chief Financial Officer
Nov 1, 2026Award+24,305––147,120
Steve Pakola
Chief Medical Officer
Nov 1, 2026Award+34,722––240,263
Patrick J. Christmas
Chief Strategy & Legal Officer
Nov 1, 2026Award+34,722––240,690
Mitchell Chan
Chief Financial Officer
Sep 1, 2026Tax withholding−4,902$9.32$45.69K122,815
Craig Malzahn
Chief Technology Officer
Sep 1, 2026Tax withholding−234$9.32$2.18K81,960
Gregory Austin Ciongoli
Director
Aug 27, 2026Buy+53,407$9.36$499.89K118,035
Gregory Austin Ciongoli
Director
Aug 26, 2026Buy+49,196$9.14$449.65K64,628
Gregory Austin Ciongoli
Director
Aug 25, 2026Award+15,432––15,432
Steve Pakola
Chief Medical Officer
Aug 1, 2026Tax withholding−7,468$9.69$72.36K205,541
Patrick J. Christmas
Chief Strategy & Legal Officer
Aug 1, 2026Tax withholding−4,699$9.69$45.53K205,968
Steve Pakola
Chief Medical Officer
Jul 2, 2026Option exercise+2,161$7.86$16.99K215,170
Steve Pakola
Chief Medical Officer
Jul 2, 2026Sale(10b5-1 plan)−2,161$13.64$29.48K213,009
Curran Simpson
Chief Executive Officer, Director
Jul 1, 2026Tax withholding−6,818$13.09$89.25K338,053
Steve Pakola
Chief Medical Officer
Jul 1, 2026Option exercise+36,725$7.86$288.66K249,734
Steve Pakola
Chief Medical Officer
Jul 1, 2026Sale(10b5-1 plan)−36,725$12.86$472.28K213,009
Curran Simpson
Chief Executive Officer, Director
Jun 30, 2026Award+1,453$10.18$14.79K344,871
Steve Pakola
Chief Medical Officer
Jun 29, 2026Sale(10b5-1 plan)−19,608$11.04$216.47K213,009
Alexandra Glucksmann
Director
May 29, 2026Award+9,807––28,861
Allan M. Fox
Director
May 29, 2026Award+9,807––28,861
Argeris N. Karabelas
Director
May 29, 2026Award+9,807––28,861
Kenneth T. Mills
Director
May 29, 2026Award+9,807––495,925
Jennifer Zachary
Director
May 29, 2026Award+9,807––31,871
Daniel Tasse
Director
May 29, 2026Award+9,807––28,861
David C. Stump
Director
May 29, 2026Award+9,807––28,861
Jean Bennett
Director
May 29, 2026Award+9,807––28,861
George V. Migausky
Director
May 29, 2026Award+9,807––28,861
Steve Pakola
Chief Medical Officer
May 11, 2026Sale(10b5-1 plan)−15,309$11.02$168.71K232,617
Steve Pakola
Chief Medical Officer
Mar 10, 2026Sale(10b5-1 plan)−5,124$10.35$53.03K247,926
Steve Pakola
Chief Medical Officer
Feb 1, 2026Tax withholding−5,267$11.16$58.78K253,050
Patrick J. Christmas
Chief Strategy & Legal Officer
Feb 1, 2026Tax withholding−4,700$11.16$52.45K210,667
Kenneth T. Mills
Director
Jan 27, 2026Option exercise+225,000$13.09$2.95M707,871
Kenneth T. Mills
Director
Jan 27, 2026Tax withholding−221,753$13.41$2.97M486,118
Craig Malzahn
Chief Technology Officer
Jan 6, 2026Award+65,847––82,194
Mitchell Chan
Chief Financial Officer
Jan 6, 2026Award+73,749––127,717
Patrick J. Christmas
Chief Strategy & Legal Officer
Jan 6, 2026Award+73,749––215,367
Curran Simpson
Chief Executive Officer, Director
Jan 6, 2026Award+144,864––342,467
Steve Pakola
Chief Medical Officer
Jan 6, 2026Award+65,847––258,317
Steve Pakola
Chief Medical Officer
Jan 2, 2026Tax withholding−18,247$14.40$262.76K192,470
Craig Malzahn
Chief Technology Officer
Jan 2, 2026Tax withholding−1,238$14.40$17.83K16,347
Patrick J. Christmas
Chief Strategy & Legal Officer
Jan 2, 2026Tax withholding−9,793$14.40$141.02K141,618
Curran Simpson
Chief Executive Officer, Director
Jan 2, 2026Tax withholding−18,559$14.40$267.25K197,603
Curran Simpson
Chief Executive Officer, Director
Dec 31, 2025Award+951$7.00$6.66K343,418
Curran Simpson
Chief Executive Officer, Director
Oct 9, 2025Sale(10b5-1 plan)−20,811$12.62$262.63K216,162
Curran Simpson
Chief Executive Officer, Director
Sep 29, 2025Sale(10b5-1 plan)−7,624$10.03$76.47K236,973
Curran Simpson
Chief Executive Officer, Director
Sep 10, 2025Sale(10b5-1 plan)−7,734$10.02$77.49K244,597
Craig Malzahn
Chief Technology Officer
Sep 1, 2025Tax withholding−234$8.93$2.09K17,585
Mitchell Chan
Chief Financial Officer
Sep 1, 2025Tax withholding−4,901$8.93$43.77K53,968
Patrick J. Christmas
Chief Strategy & Legal Officer
Aug 1, 2025Tax withholding−4,699$8.19$38.48K151,411
Curran Simpson
Chief Executive Officer, Director
Jul 1, 2025Tax withholding−4,701$8.23$38.69K252,331
Jennifer Zachary
Director
May 30, 2025Award+7,768––22,064
George V. Migausky
Director
May 30, 2025Award+7,768––19,054
Kenneth T. Mills
Director
May 30, 2025Award+7,768––482,871
Daniel Tasse
Director
May 30, 2025Award+7,768––19,054
Argeris N. Karabelas
Director
May 30, 2025Award+7,768––19,054
Allan M. Fox
Director
May 30, 2025Award+7,768––19,054
Jean Bennett
Director
May 30, 2025Award+7,768––19,054
Alexandra Glucksmann
Director
May 30, 2025Award+7,768––19,054
David C. Stump
Director
May 30, 2025Award+7,768––19,054
Kenneth T. Mills
Director
May 12, 2025Sale(10b5-1 plan)−20,602$7.91$162.96K475,103

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
16.69%
10M shares short
Days to cover
8.3
At 1M shares a day
Change since last report
+1.4%
From 10M shares
Short volume, 20 days
53.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Regenxbio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 24,999 shares on Sep 30, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Stephen J. Pakola
Officer
Jul 1, 202643,206$517.61KJul 1, 2026Exercise of Stock Options
Stephen Pakola
Officer
May 11, 202634,917$368.37KMay 11, 2026Restricted Stock Units
Stephen J Pakola
Officer
Mar 10, 20265,124$53.19KMar 10, 2026Restricted Stock Units
Curran Simpson
Director, Officer
Oct 9, 202520,811$254.31KOct 9, 2025Restricted Stock Units
Curran Simpson
Director, Officer
Sep 10, 202515,358$151.89KSep 10, 2025Restricted Stock Units
Kenneth T. Mills
Director
May 12, 202520,602$154.93KMay 12, 2025Exercise of Stock Options
Vittal Vasista
Officer
Dec 30, 202420,041$148.50KDec 30, 2024Previously Exercised Stock Options
Argeris N. Karabelas
Director
Aug 1, 202431,000$441.75KAug 1, 2024Exercise of Stock Options
Curran Simpson
Director, Officer
Jul 29, 202425,106$359.77KJul 29, 2024Restricted Stock Units
Argeris N. Karabelas
Director
Jul 1, 202430,000$351.00KJul 1, 2024Exercise of Stock Options
Kenneth T. Mills
Director, Officer
May 14, 202445,000$708.30KMay 14, 2024Exercise of Stock Options
Stephen J Pakola
Officer
Mar 5, 202412,878$275.07KMar 5, 2024Exercise of Stock Options
Kenneth T. Mills
Director, Officer
Jan 16, 202490,000$1.36MJan 16, 2024Exercise of Stock Options
Stephen J Pakola
Officer
Jan 3, 202417,237$316.13KJan 3, 2024Restricted Stock Units
Kenneth T. Mills
Director, Officer
Dec 19, 202345,000$877.95KDec 19, 2023Exercise of Stock Options

Congress trades

2 trades in Regenxbio reported by 1 member of the House

MemberTypeTradedAmountFiled
Peter Welch
VT00
SoldNov 8, 2019$1K–15KNov 14, 2019
Peter Welch
VT00
BoughtOct 22, 2019$1K–15KNov 14, 2019

See a number that looks wrong?